Pharma Sector

The inspection finished with no observations, and the facility was classified as "No Action Indicated" (NAI).

It has entered into a share purchase agreement to acquire a 100% equity stake in Chalasani Hospitals Pvt Ltd.

Currently, more than 70 Kaya skin clinics nationwide and some of the top e-commerce platforms carry Kaya's products.

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Fenofibrate is a drug used to treat high cholesterol and triglyceride levels in the blood, which helps with cardiovascular health management.

According to reports, the sanctions were imposed as a result of their participation in "pay-for-delay" arrangements from 2005 to 2007.

Earlier on June 25, about 3.6 lakh shares of Alkem Laboratories Ltd were traded in a block deal worth ₹117.8 Crore before the market opened.

From March 28 to April 4, 2024, the US drug regulator conducted a normal current Good Manufacturing Practices (cGMP) inspection at the site.

The block deal has a floor price of ₹331 per share, which is 7.1% lower than Thursday's closing price, according to sources.

Cipla stated in an exchange statement that this extra investment, made through a convertible loan, will accelerate the company's engagement in the mRNA space.